China Resources Pharmaceutical Group Ltd.
3320
Rangering i aksjer
#4326
China Resources Pharmaceutical Group Limited, an investment holding company,... China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Aksjekurs
$0.57950582
Markedsverdi
$3.64B
Endring (1 dag)
-2.69%
Endring (1 år)
-5.97%
Land
HK
Handel China Resources Pharmaceutical Group Ltd. (3320)
Kategori
Healthcare
Inntekter for China Resources Pharmaceutical Group Ltd. (3320)
Inntekter i Jun 2026 TTM: $1.71B
Ifølge China Resources Pharmaceutical Group Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat $1.71B. I 2023 hadde selskapet et resultat på $1.39B, en økning sammenlignet med resultatet i 2022, som var $1.26B. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for China Resources Pharmaceutical Group Ltd. fra 2013 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $1.71B | 13.87% |
| 2024 | $1.50B | 7.62% |
| 2023 | $1.39B | 10.35% |
| 2022 | $1.26B | 16.96% |
| 2021 | $1.08B | 18.19% |
| 2020 | $912.56M | 9.36% |
| 2019 | $834.45M | -28.83% |
| 2018 | $1.17B | 6.72% |
| 2017 | $1.10B | 5.89% |
| 2016 | $1.04B | -0.13% |
| 2015 | $1.04B | 16.37% |
| 2014 | $892.63M | 0.13% |
| 2013 | $891.51M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $1.35B | -20.87% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -98.45% |
US
|
